Illumina Ventures, a venture capital firm, and Omnimed Capital, an investment firm, led a $28.7m Series C financing round in Pattern Bioscience, a clinical diagnostics company, with participation from AMR Action Fund and Daleshaw. “We are grateful for the support from our investors as we strive to revolutionize bacterial testing with our single-cell microbiology platform. We believe our technology will significantly impact patient outcomes and help tackle the growing challenge of antibiotic resistance,” Nick Arab, Pattern Bioscience Co-Founder and CEO.